[
  {
    "ts": null,
    "headline": "Fidelity OTC Portfolio Q2 2025 Commentary",
    "summary": "Fidelity Investments reports a 16.2% Q2 gain for its OTC Portfolio, fueled by AI-driven tech picks. Explore how durable growth shapes their strategy.",
    "url": "https://finnhub.io/api/news?id=ad12498be383b776d01321a84d0f4fd0c0bc4e74dd53016195710d73db44091b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753389600,
      "headline": "Fidelity OTC Portfolio Q2 2025 Commentary",
      "id": 136082479,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160051571/image_1160051571.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Fidelity Investments reports a 16.2% Q2 gain for its OTC Portfolio, fueled by AI-driven tech picks. Explore how durable growth shapes their strategy.",
      "url": "https://finnhub.io/api/news?id=ad12498be383b776d01321a84d0f4fd0c0bc4e74dd53016195710d73db44091b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=187437c3bb8120d790e0249778139fb68e9bbc8c64e9bd339095614c9de96ba3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753375560,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 136139542,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=187437c3bb8120d790e0249778139fb68e9bbc8c64e9bd339095614c9de96ba3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $547.93 as of July 16th. REGN’s trailing and forward P/E were 13.93 and 15.29 respectively according to Yahoo Finance. Regeneron (REGN) presents […]",
    "url": "https://finnhub.io/api/news?id=e373f16bbb88850ac32d44ed65c4b7037804996c078f3e3b9bc68c2aac9c52dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753359970,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
      "id": 136066629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $547.93 as of July 16th. REGN’s trailing and forward P/E were 13.93 and 15.29 respectively according to Yahoo Finance. Regeneron (REGN) presents […]",
      "url": "https://finnhub.io/api/news?id=e373f16bbb88850ac32d44ed65c4b7037804996c078f3e3b9bc68c2aac9c52dc"
    }
  },
  {
    "ts": null,
    "headline": "Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip",
    "summary": "Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 5.33% in the second quarter, compared to the S&P 500’s 10.94% return and the Russell 1000 Value’s 3.79% return. The firm’s stock price performance was volatile, but its confidence […]",
    "url": "https://finnhub.io/api/news?id=27edb365287305200ace5cb6d9577e31f035022dafda7eb0ad2d3c7e8b5e1bd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753359646,
      "headline": "Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip",
      "id": 136066630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 5.33% in the second quarter, compared to the S&P 500’s 10.94% return and the Russell 1000 Value’s 3.79% return. The firm’s stock price performance was volatile, but its confidence […]",
      "url": "https://finnhub.io/api/news?id=27edb365287305200ace5cb6d9577e31f035022dafda7eb0ad2d3c7e8b5e1bd2"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Contrafund Q2 2025 Commentary",
    "summary": "Fidelity Contrafund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=f41b1053b16d2cd041d9051d528960194cf1faaa7c3f62fe170a46de00d23734",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753358400,
      "headline": "Fidelity Contrafund Q2 2025 Commentary",
      "id": 136068338,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f41b1053b16d2cd041d9051d528960194cf1faaa7c3f62fe170a46de00d23734"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation",
    "summary": "TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and",
    "url": "https://finnhub.io/api/news?id=12d2009974899e748bd049427de28e0ef6d84a5ef5dccf0801c0fe2fbe6f06a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753356600,
      "headline": "Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation",
      "id": 136066631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and",
      "url": "https://finnhub.io/api/news?id=12d2009974899e748bd049427de28e0ef6d84a5ef5dccf0801c0fe2fbe6f06a9"
    }
  },
  {
    "ts": null,
    "headline": "3 Low-Volatility Stocks We Steer Clear Of",
    "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
    "url": "https://finnhub.io/api/news?id=52d28bcf3def2999870fc736ca4e458dba64d4acbce3b34cb9ef4e5410d709ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753331781,
      "headline": "3 Low-Volatility Stocks We Steer Clear Of",
      "id": 136066632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
      "url": "https://finnhub.io/api/news?id=52d28bcf3def2999870fc736ca4e458dba64d4acbce3b34cb9ef4e5410d709ea"
    }
  }
]